Adamas Appoints Mardi C. Dier to its Board of Directors
October 11 2017 - 6:16PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the
appointment of Mardi C. Dier, Chief Financial Officer of Portola
Pharmaceuticals, Inc., to its Board of Directors. Ms. Dier will
serve on the Audit Committee. Ms. Dier brings over 25 years of
financial management experience in the biotechnology industry. In
addition, Adamas announced that Richard H. Booth has retired from
the Adamas Board, effective immediately.
“First, I would like to thank Richard for his
years of service to Adamas, during which time we brought Adamas
public, financed GOCOVRI™ through FDA approval and launch, as well
as funded the expansion of our pipeline into multiple sclerosis,”
said Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive
Officer of Adamas Pharmaceuticals, Inc. “We welcome Mardi to the
Board. Her 25 years of public finance and company building
experience will be invaluable as we evolve into a commercial
company with the launch of GOCOVRI.”
“I am excited to work with the Adamas Board of
Directors and management team as the company brings its
FDA-approved therapy, GOCOVRI, to patients,” said Ms. Dier.
“Adamas’ unique approach to drug discovery and development for the
treatment of chronic neurological disorders is an exciting area of
medicine. I look forward to partnering with the team to help the
company reach its long-term goals.”
Mardi C. Dier has served as Executive Vice
President and Chief Financial Officer of Portola Pharmaceuticals
since November 2013 after joining the company in August 2006. At
Portola, Mardi has overseen the development of the accounting,
finance, global supply chain, investor relations, communications,
IT and facilities functions, and has led the raising of over $1.25
billion in capital. Previously, she served as Vice President of
Investor Relations at Chiron Corporation from 2003 until its
acquisition by Novartis Pharmaceuticals in April 2006. Prior to
joining Chiron, she served as a Director in the West Coast
investment banking practice at Prudential Securities, where she
focused on biotechnology and other life sciences companies. Ms.
Dier was previously at KPMG Peat Marwick in the audit department.
She holds a B.S. in biology from Stanford University and an M.B.A.
from The Anderson School at the University of California, Los
Angeles. In 2013, Ms. Dier was recognized as one of the most
influential Bay Area business women by the San Francisco Business
Times and was a finalist for its Bay Area CFO of the Year
Award.
About Adamas Pharmaceuticals,
Inc.At Adamas, we believe in the power and the promise of
medicines derived from a deep understanding of time-dependent
biology. Our expertise lies in uncovering and mapping the
relationship between disease and drug activity. From there, we
strive to create medicines with therapeutic profiles that match the
pattern of disease to drive a more significant and durable clinical
effect. This understanding of time-dependent biological processes
informs our every innovation, targeting advancement in treatment of
chronic neurologic disorders. Our portfolio includes:
GOCOVRI™ (amantadine) extended release capsules (previously
ADS-5102), the first and only FDA-approved medicine for the
treatment of dyskinesia in patients with Parkinson’s disease
receiving levodopa-based therapy, with or without concomitant
dopaminergic medications; ADS-5102 in development for the treatment
of multiple sclerosis walking impairment and additional indications
in Parkinson’s disease; and ADS-4101, a high-dose, modified-release
lacosamide in development for the treatment of partial onset
seizures in patients with epilepsy. Additionally, Adamas’ licensed
assets are currently marketed by Allergan under the brand names
NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive
royalties on sales of these medicines beginning in June 2018 and
May 2020, respectively. For more information, please visit
www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz
Pharma GmbH & Co. KGaA.
Contact:
Investor Ashleigh
BarretoDirector, Corporate Communications & Investor
RelationsAdamas Pharmaceuticals,
Inc.510-450-3567ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2023 to Apr 2024